series-c-plus
Stage
4
Investors
About
KSQ Therapeutics develops CRISPR/Cas9-engineered tumor infiltrating lymphocyte therapies and leverages its CRISPRomics platform to discover therapeutic targets for the treatment of cancer.
Explore KSQ Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.